Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898587 | 1.00 | PNMT (0.43) | PNMTEPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL29430517 | 0.95 | PNMT (0.47) | PNMTEPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL3459355 | 0.95 | PNMT (0.47) | PNMTEPHX1ALDH1A1NPC1RAB9A | |
| Water SCHEMBL15362024 | 0.94 | PNMT (0.46) | PNMTEPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL28324367 | 0.91 | PNMT (0.41) | PNMTEPHX1NPC1RAB9APRSS1 | |
| Glycine SCHEMBL25183413 | 0.91 | PNMT (0.49) | PNMTEPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL8050275 | 0.86 | PNMT (0.39) | PNMTEPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL5045467 | 0.85 | HTT (0.43) | PNMTEPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL6030527 | 0.85 | HTT (0.47) | PNMTEPHX1ALDH1A1NPC1RAB9A | |
| SCHEMBL29541016 | 0.85 | HTT (0.47) | PNMTEPHX1ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924669-A | Carboxyl functionalized super-crosslinked polymer and preparation method and application thereof | 中南民族大学 | 2024-04-26 | — | — | CN | claimed |
| EP-4714956-A2 | IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-12503489-B2 | Method for producing antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-12-23 | — | — | US | disclosed |
| EP-3677589-B1 | IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2025-11-26 | — | — | EP | disclosed |
| US-20240376147-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-11-14 | — | — | US | disclosed |
| CN-117924669-A | Carboxyl functionalized super-crosslinked polymer and preparation method and application thereof | 中南民族大学 | 2024-04-26 | — | — | CN | disclosed |
| US-11945882-B2 | Method for producing antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-02 | — | — | US | disclosed |
| US-20200385422-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3677589-A1 | IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-08 | — | — | EP | disclosed |
| CN-111051330-A | Improved preparation method of antibody-drug conjugate | 第一三共株式会社 | 2020-04-21 | — | — | CN | disclosed |
| EP-0295316-B1 | Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones | AMERICAN CYANAMID CO (US) | 1995-11-08 | — | — | EP | disclosed |
| US-5130307-A | Antibody inhibitors; treating organ graft rejection, fungal infections; antiinflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-14 | — | — | US | disclosed |
| EP-0489220-A1 | Cytotoxic N,N'-bis (succinyl-peptide-) derivatives of 1,4-bis (aminoalkyl)-5,8-dihydroxyanthraquinones and antibody conjugates thereof | AMERICAN CYANAMID COMPANY (US) | 1992-06-10 | — | — | EP | disclosed |
| EP-0295316-A2 | Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4732970-A | Antitumor amino acid and peptide derivatives of 1,4-bis(aminoalkyl and hydroxy-aminoalkyl)amino)-5,8-dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385422-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | UGT1A9, ALB, MRPL21 | PNMT 3499/4885EPHX1 1623/4885ALDH1A1 257/4885 |
| US-12503489-B2 | Method for producing antibody-drug conjugate | UGT1A9, ALB, MRPL21 | PNMT 3499/4885EPHX1 1623/4885ALDH1A1 257/4885 |
| US-20240376147-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | UGT1A9, ALB, MRPL21 | PNMT 3499/4885EPHX1 1623/4885ALDH1A1 257/4885 |
| US-11945882-B2 | Method for producing antibody-drug conjugate | UGT1A9, ALB, MRPL21 | PNMT 3499/4885EPHX1 1623/4885ALDH1A1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.